Gibson, Dunn & Crutcher LLP is Advising KKR on its Investment Alongside Ampersand Capital Partners in Alliance Pharma

May 17, 2022

Gibson, Dunn & Crutcher LLP is advising KKR on its investment, alongside Ampersand Capital Partners, in Alliance Pharma. Alliance Pharma, a US-based bioanalytical CRO and an Ampersand portfolio company, has agreed to acquire Drug Development Solutions (DDS), a European provider of bioanalytical solutions, from LGC. More information can be found in the announcement release.

The Gibson Dunn team is led by partners Till Lefranc and Branden Berns. Partners Jeffrey Trinklein and Sandy Bhogal and associates Alex Marcellesi and Bridget English are advising on tax aspects. Partners Ali Nikpay and Deirdre Taylor, of counsel Jessica Staples, and associate Ben Nunez are advising on antitrust aspects.